In most cases, non-melanoma skin cancers are caused by overexposure to ultraviolet radiation - the invisible rays from the sun that can burn the skin. To reduce the risk of skin cancer, dermatologists encourage the public to Be Sun Smart®, including limiting sun exposure and using broad-spectrum sunscreens. Despite these efforts, the incidence of non-melanoma skin cancer continues to rise. Now, several agents - including medicines, foods and vitamins - are being investigated for their chemopreventive properties, or ability to prevent skin cancer.
At the American Academy of Dermatology's Summer Academy Meeting 2010 in Chicago, dermatologist Craig A. Elmets, MD, FAAD, professor and chair, department of dermatology, and director of the Skin Diseases Research Center, University of Alabama at Birmingham, discussed promising new research on the use of medicine and diet to prevent UV-induced skin cancer in the future.
"Based on the research conducted thus far, it appears that several different agents have the potential to be effective in providing enhanced sun protection and preventing non-melanoma skin cancers," said Dr. Elmets. "While the way these agents work are different, we have seen encouraging results with both oral and topical agents, including non-steroidal anti-inflammatory drugs (NSAIDs), eflornithine and certain natural antioxidants."
Medications Being Investigated as Future Chemopreventive Agents
NSAIDs are a class of drugs that block cyclooxygenase enzymes (COX-1 and COX-2), which produce prostaglandins that promote inflammation, pain, and fever. When these enzyme messengers that are responsible for reducing prostaglandins throughout the body are blocked, ongoing inflammation, pain, and fever are reduced. One such NSAID approved by the Food & Drug Administration (FDA) and used primarily to treat inflammation associated with arthritis is celecoxib. Dr. Elmets explained that this oral medication has been shown to be an effective chemopreventive agent in patients with a syndrome known as basal cell nevus syndrome. Caused by a genetic defect, basal cell nevus syndrome triggers patients to develop basal cell carcinomas at a very young age.
"In patients with basal cell cacinomas, investigators have found that the COX-2 enzyme is elevated in non-melanoma skin cancers. Because celecoxib inhibits this enzyme, clinical studies have demonstrated that taking celecoxib seems to decrease the number of new basal cell carcinomas in basal cell nevus syndrome," noted Dr. Elmets. "This is very encouraging, particularly if this can eventually be applied to basal cell skin cancer in the general population."
According to Dr. Elmets, eflornithine is another drug that has been shown to have beneficial effects in preventing basal cell carcinoma. FDA-approved as a topical treatment for excessive hair growth and as an injectable formulation to treat sleeping sickness, eflornithine inhibits the enzyme known as ornithine decarboxylase that is found to be elevated in skin cancers.
"Although celecoxib and eflornithine work by different mechanisms, initial studies show that they both prevent basal cell carcinomas by at least 30 percent," said Dr. Elmets. "Based on these initial findings, these two drugs are considered very promising as chemopreventive agents and require additional clinical study."